Correction: miR155, TREM2, INPP5D: Disease stage and cell-type are essential considerations when targeting clinical interventions based on mouse models of Alzheimer's amyloidopathy

J Neuroinflammation. 2023 Nov 30;20(1):288. doi: 10.1186/s12974-023-02954-z.

Sam Gandy^{1

2

3}, Michelle E Ehrlich^{4

5

6}

¹ Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. samuel.gandy@mssm.edu.
² Department of Psychiatry and Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. samuel.gandy@mssm.edu.
³ James J Peters VA Medical Center, Bronx, NY, 10468, USA. samuel.gandy@mssm.edu.
⁴ Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. michelle.ehrlich@mssm.edu.
⁵ Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. michelle.ehrlich@mssm.edu.
⁶ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. michelle.ehrlich@mssm.edu.

No abstract available

Publication types